Astel­las gath­ers scat­tered cell and gene ther­a­py, BD units in new $70M South San Fran­cis­co hub

Bring­ing all its West Coast-based units un­der one roof, Astel­las has un­veiled plans to pour $70 mil­lion in­to a new biotech cam­pus in South San Fran­cis­co.

With cell and gene ther­a­pies as the dom­i­nant theme, the Japan­ese phar­ma spot­light­ed Astel­las Gene Ther­a­pies and Xyphos Bio­sciences, which is de­vel­op­ing cell ther­a­pies for sol­id tu­mors, as the two big sub­sidiaries that will oc­cu­py the space. Those work­ing in the busi­ness de­vel­op­ment team and the Rx+ Busi­ness Ac­cel­er­a­tor are al­so set to move in with them.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER